Publication of Circular

Summary by AI ^BETAClose X

Immupharma PLC has announced the publication of a circular to shareholders, following its fundraising announcement on March 17, 2026. This circular details a General Meeting scheduled for April 7, 2026, at 11:00 a.m. GMT, where further resolutions related to the fundraising will be discussed. A copy of the circular will be available on the company's website.

Disclaimer*

Immupharma PLC

19 March 2026

ImmuPharma PLC

("ImmuPharma" or the "Company")

Publication of Circular

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company announces that further to its 'Fundraising' announcement, published on 17 March 2026 at 7:00 a.m. (the "Fundraising RNS"), a circular convening a General Meeting has today been sent to shareholders.

The General Meeting is scheduled to be held at 11.00 a.m. (GMT) on 7 April 2026, at the offices of Broadfield Law UK LLP, One Bartholomew Close, London EC1A 7BL.

A copy of the Circular will be available shortly, in electronic form, for download on the Company's website www.immupharma.co.uk.

Terms used but not defined in this announcement have the same meaning as set out in the Fundraising RNS.

For further information, please contact:

ImmuPharma PLC (www.immupharma.co.uk.)

Tim McCarthy, Chief Executive Officer

Lisa Baderoon, Head of Investor Relations

+44 (0) 207 206 2650

+ 44 (0) 7721 413496

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

+44 (0) 203 368 3550

Stanford Capital Partners (Joint Broker)

Patrick Claridge, Bob Pountney

44 (0) 20 3650 3650

SI Capital (Joint Broker)

Nick Emerson

+44 (0) 1483 413500

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives.

For additional information about ImmuPharma please visit www.immupharma.co.uk.

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END